|
Apr 27, 2022
|
European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva
|
|
|
Apr 21, 2022
|
BioCryst to Report First Quarter 2022 Financial Results on May 5
|
|
|
Apr 11, 2022
|
BioCryst to Present at Upcoming Investor Conference
|
|
|
Apr 08, 2022
|
BioCryst Pauses Enrollment in BCX9930 Clinical Trials
|
|
|
Apr 05, 2022
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Mar 03, 2022
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
Mar 02, 2022
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Feb 24, 2022
|
BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)
|
|
|
Feb 23, 2022
|
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
|
|
|
Feb 22, 2022
|
BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases
|
|
